BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. Journal of Hepatology 2006;44:1167-74. [DOI: 10.1016/j.jhep.2006.02.011] [Cited by in Crossref: 347] [Cited by in F6Publishing: 348] [Article Influence: 21.7] [Reference Citation Analysis]
Number Citing Articles
1 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
2 Mack CL. Serum cytokines as biomarkers of disease and clues to pathogenesis. Hepatology 2007;46:6-8. [DOI: 10.1002/hep.21793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
3 Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari G, Iraj B. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res 2016;5:28. [PMID: 27014655 DOI: 10.4103/2277-9175.176368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
4 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Koek G, Liedorp P, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clinica Chimica Acta 2011;412:1297-305. [DOI: 10.1016/j.cca.2011.04.013] [Cited by in Crossref: 202] [Cited by in F6Publishing: 195] [Article Influence: 18.4] [Reference Citation Analysis]
6 Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7:471-479. [PMID: 22962039 DOI: 10.1111/j.2047-6310.2012.00082.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
7 Chiu CC, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, Yang SS, Huang WC, Chuang HL. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients 2017;9:E1220. [PMID: 29113135 DOI: 10.3390/nu9111220] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
8 Devisscher L, Verhelst X, Colle I, Van Vlierberghe H, Geerts A. The role of macrophages in obesity-driven chronic liver disease. Journal of Leukocyte Biology 2016;99:693-8. [DOI: 10.1189/jlb.5ru0116-016r] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
9 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
10 Gentile P, Sarlo F, De Angelis B, De Lorenzo A, Cervelli V. Obesity phenotypes and resorption percentage after breast autologous fat grafting: Rule of low-grade inflammation. Adv Biomed Res 2016;5:134. [PMID: 27656603 DOI: 10.4103/2277-9175.187396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
12 Soares e Silva AK, de Oliveira Cipriano Torres D, dos Santos Gomes FO, dos Santos Silva B, Lima Ribeiro E, Costa Oliveira A, dos Santos LA, de Lima Mdo C, Pitta Ida R, Peixoto CA. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). PLoS One 2015;10:e0123787. [PMID: 25875942 DOI: 10.1371/journal.pone.0123787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
13 Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196-201. [PMID: 19669304 DOI: 10.1007/s12072-008-9058-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
14 Kirovski G, Dorn C, Huber H, Moleda L, Niessen C, Wobser H, Schacherer D, Buechler C, Wiest R, Hellerbrand C. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. Exp Mol Pathol. 2011;91:780-783. [PMID: 21855538 DOI: 10.1016/j.yexmp.2011.08.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
15 Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Järvinen H. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2008;295:E85-91. [PMID: 18430964 DOI: 10.1152/ajpendo.90224.2008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
16 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 30.2] [Reference Citation Analysis]
17 Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond). 2008;115:1-12. [PMID: 19016656 DOI: 10.1042/cs20070311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
18 Parker R, Weston CJ, Miao Z, Corbett C, Armstrong MJ, Ertl L, Ebsworth K, Walters MJ, Baumart T, Newland D, McMahon J, Zhang P, Singh R, Campbell J, Newsome PN, Charo I, Schall TJ, Adams DH. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2018;314:G483-93. [PMID: 29420066 DOI: 10.1152/ajpgi.00213.2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
19 Liu L, Mei M, Yang S, Li Q. Roles of chronic low-grade inflammation in the development of ectopic fat deposition. Mediators Inflamm. 2014;2014:418185. [PMID: 25143667 DOI: 10.1155/2014/418185] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
20 Li S, Liao X, Meng F, Wang Y, Sun Z, Guo F, Li X, Meng M, Li Y, Sun C. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One. 2014;9:e86724. [PMID: 24489777 DOI: 10.1371/journal.pone.0086724] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
21 Ju J, Zheng Z, Xu YJ, Cao P, Li J, Li Q, Liu Y. Influence of total polar compounds on lipid metabolism, oxidative stress and cytotoxicity in HepG2 cells. Lipids Health Dis 2019;18:37. [PMID: 30709407 DOI: 10.1186/s12944-019-0980-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Volovelsky O, Weiss R. Fatty liver disease in obese children – relation to other metabolic risk factors. Int J Pediatr Obes 2011;6:59-64. [DOI: 10.3109/17477166.2011.583661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
23 Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, Puri P, Sanyal AJ. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 2016;30:4071-82. [PMID: 27553225 DOI: 10.1096/fj.201600427R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zheng T, Chen B, Yang L, Hu X, Zhang X, Liu H, Qin L. Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. Metabolism 2017;73:125-34. [DOI: 10.1016/j.metabol.2017.04.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
25 Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, Chen B, Li X, Zu M, Zhou D. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol. 2012;685:156-164. [PMID: 22546234 DOI: 10.1016/j.ejphar.2012.04.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
26 Kamada Y, Mori K, Matsumoto H, Kiso S, Yoshida Y, Shinzaki S, Hiramatsu N, Ishii M, Moriwaki K, Kawada N, Takehara T, Miyoshi E. N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis. Glycobiology 2012;22:778-87. [DOI: 10.1093/glycob/cws012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, George DL, Ahima RS, Murphy ME. The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Rep 2016;14:2413-25. [PMID: 26947067 DOI: 10.1016/j.celrep.2016.02.037] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
28 Tripathi DM, Rohilla S, Kaur I, Siddiqui H, Rawal P, Juneja P, Kumar V, Kumari A, Naidu VGM, Ramakrishna S, Banerjee S, Puria R, Sarin SK, Kaur S. Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH. Int J Mol Sci 2021;22:8489. [PMID: 34445195 DOI: 10.3390/ijms22168489] [Reference Citation Analysis]
29 Han E, Kim MK, Jang BK, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Diabetes Metab J 2021;45:698-707. [PMID: 33517613 DOI: 10.4093/dmj.2020.0118] [Reference Citation Analysis]
30 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
31 Morikawa R, Nakamoto N, Amiya T, Chu PS, Koda Y, Teratani T, Suzuki T, Kurebayashi Y, Ueno A, Taniki N, Miyamoto K, Yamaguchi A, Shiba S, Katayama T, Yoshida K, Takada Y, Ishihara R, Ebinuma H, Sakamoto M, Kanai T. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol 2021;74:511-21. [PMID: 33038434 DOI: 10.1016/j.jhep.2020.09.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Shahmohammadi HA, Hosseini SA, Hajiani E, Malehi AS, Alipour M. Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45609] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
33 Wang C, Duan X, Sun X, Liu Z, Sun P, Yang X, Sun H, Liu K, Meng Q. Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice. Food Funct 2016;7:3716-23. [DOI: 10.1039/c6fo00773b] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
34 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Damavandi N, Zeinali S. Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF-α and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease. Mol Biol Rep 2021;48:1225-31. [PMID: 33492571 DOI: 10.1007/s11033-021-06142-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014.00177] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 9.8] [Reference Citation Analysis]
37 Zhao L, Chen Y, Tang R, Chen Y, Li Q, Gong J, Huang A, Varghese Z, Moorhead JF, Ruan XZ. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J Gastroenterol Hepatol. 2011;26:875-883. [PMID: 21488946 DOI: 10.1111/j.1440-1746.2010.06560.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 5.3] [Reference Citation Analysis]
38 Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380-388. [PMID: 19501927 DOI: 10.1016/j.jhep.2009.03.025] [Cited by in Crossref: 188] [Cited by in F6Publishing: 182] [Article Influence: 14.5] [Reference Citation Analysis]
39 Shini S, Shini A, Bryden WL. Unravelling fatty liver haemorrhagic syndrome: 1. Oestrogen and inflammation. Avian Pathol 2020;49:87-98. [PMID: 31565961 DOI: 10.1080/03079457.2019.1674444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ciardullo S, Muraca E, Zerbini F, Manzoni G, Perseghin G. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. J Clin Endocrinol Metab 2021;106:e2856-65. [PMID: 33878156 DOI: 10.1210/clinem/dgab262] [Reference Citation Analysis]
41 Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Semin Liver Dis 2021. [PMID: 34794182 DOI: 10.1055/s-0041-1739455] [Reference Citation Analysis]
42 Wang HL, Zhang H, Wu SL, Liao GC, Fang AP, Zhu MF, Zhu HL. Red blood cell count has an independent contribution to the prediction of ultrasonography-diagnosed fatty liver disease. PLoS One 2017;12:e0172027. [PMID: 28187211 DOI: 10.1371/journal.pone.0172027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Cardoso-saldaña GC, Medina-urrutia AX, Posadas-romero C, Juárez-rojas JG, Jorge-galarza E, Vargas-alarcón G, Posadas-sánchez R. Fatty liver and abdominal fat relationships with high C-reactive protein in adults without coronary heart disease. Annals of Hepatology 2015;14:658-65. [DOI: 10.1016/s1665-2681(19)30760-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Gudbrandsen OA, Wergedahl H, Liaset B, Espe M, Mørk S, Berge RK. Dietary single cell protein reduces fatty liver in obese Zucker rats. Br J Nutr 2008;100:776-85. [DOI: 10.1017/s0007114508960906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
45 Zhang T, Zhang Y, Zhang C, Tang F, Li H, Zhang Q, Lin H, Wu S, Liu Y, Xue F. Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS One. 2014;9:e96651. [PMID: 24801211 DOI: 10.1371/journal.pone.0096651] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
46 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
47 Bertola A, Bonnafous S, Cormont M, Anty R, Tanti JF, Tran A, Le Marchand-Brustel Y, Gual P. Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway. J Biol Chem. 2007;282:10325-10332. [PMID: 17284447 DOI: 10.1074/jbc.M611770200] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
48 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 176] [Cited by in F6Publishing: 157] [Article Influence: 22.0] [Reference Citation Analysis]
49 Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313-326. [PMID: 21040935 DOI: 10.1016/j.metabol.2010.09.003] [Cited by in Crossref: 183] [Cited by in F6Publishing: 180] [Article Influence: 15.3] [Reference Citation Analysis]
50 Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670-678. [PMID: 18666225 DOI: 10.1002/hep.22399] [Cited by in Crossref: 136] [Cited by in F6Publishing: 143] [Article Influence: 9.7] [Reference Citation Analysis]
51 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One. 2009;4:e7929. [PMID: 19936233 DOI: 10.1371/journal.pone.0007929] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
52 Haukeland JW, Aukrust P. Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome. Journal of Hepatology 2006;45:881-2. [DOI: 10.1016/j.jhep.2006.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev 2019;32:128-45. [PMID: 30707092 DOI: 10.1017/S0954422418000239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
54 Zardi EM, Dobrina A, Amoroso A, Afeltra A. Prostacyclin in liver disease: a potential therapeutic option. Expert Opin Biol Ther 2007;7:785-90. [PMID: 17555364 DOI: 10.1517/14712598.7.6.785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
55 Abo El-khair SM, Ghoneim FM, Shabaan DA, Elsamanoudy AZ. Molecular and ultrastructure study of endoplasmic reticulum stress in hepatic steatosis: role of hepatocyte nuclear factor 4α and inflammatory mediators. Histochem Cell Biol 2020;153:49-62. [DOI: 10.1007/s00418-019-01823-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Zhao L, Zhong S, Qu H, Xie Y, Cao Z, Li Q, Yang P, Varghese Z, Moorhead JF, Chen Y, Ruan XZ. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci Rep 2015;5:10222. [PMID: 25974206 DOI: 10.1038/srep10222] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
57 Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, Gao M, Yao Z, Zhang S, Zhao Y, Xie L, Chen Z. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun 2021;12:7213. [PMID: 34893641 DOI: 10.1038/s41467-021-27539-3] [Reference Citation Analysis]
58 Schindhelm RK, Diamant M, Heine RJ. Nonalcoholic fatty liver disease and cardiovascular disease risk. Curr Diab Rep 2007;7:181-7. [PMID: 17547835 DOI: 10.1007/s11892-007-0030-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
59 Lv Q, Zhen Q, Liu L, Gao R, Yang S, Zhou H, Goswami R, Li Q. AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells. Life Sci 2015;131:23-9. [PMID: 25817233 DOI: 10.1016/j.lfs.2015.03.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
60 Egan CE, Daugherity EK, Rogers AB, Abi Abdallah DS, Denkers EY, Maurer KJ. CCR2 and CD44 promote inflammatory cell recruitment during fatty liver formation in a lithogenic diet fed mouse model. PLoS One 2013;8:e65247. [PMID: 23762326 DOI: 10.1371/journal.pone.0065247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
61 Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel) 2021;11:689. [PMID: 33921359 DOI: 10.3390/diagnostics11040689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Wang Y, Wang G, Bai J, Zhao N, Wang Q, Zhou R, Li G, Hu C, Li X, Tao K, Xia Z, Wang G. Role of Indole-3-Acetic Acid in NAFLD Amelioration After Sleeve Gastrectomy. OBES SURG 2021;31:3040-52. [DOI: 10.1007/s11695-021-05321-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Al-Gayyar MM, Shams ME, Barakat EA. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. Pharm Biol. 2012;50:297-303. [PMID: 22103753 DOI: 10.3109/13880209.2011.604088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
64 Kountouras J, Papaefthymiou A, Polyzos SA, Deretzi G, Vardaka E, Soteriades ES, Tzitiridou-Chatzopoulou M, Gkolfakis P, Karafyllidou K, Doulberis M. Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms 2021;9:2351. [PMID: 34835476 DOI: 10.3390/microorganisms9112351] [Reference Citation Analysis]
65 Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036-1042. [PMID: 18177455 DOI: 10.1111/j.1572-0241.2007.01709.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 134] [Article Influence: 9.0] [Reference Citation Analysis]
66 Bi X, Liu W, Xia X, Chen L, Mu T, Liu J, Hou Y, Zhao Y. Effects of Callistephus chinensis flower polyphones on improving metabolic disorders in high-fat diet-induced mice. Food Funct 2014;5:3304-10. [PMID: 25367327 DOI: 10.1039/c4fo00637b] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Fuchs M. New Medical Treatment Strategies for Nonalcoholic Steatohepatitis. Curr Treat Options Gastro 2015;13:259-73. [DOI: 10.1007/s11938-015-0053-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, Yarmush ML, Alaniz RC, Jayaraman A, Lee K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 2018;23:1099-1111. [PMID: 29694888 DOI: 10.1016/j.celrep.2018.03.109] [Cited by in Crossref: 160] [Cited by in F6Publishing: 144] [Article Influence: 53.3] [Reference Citation Analysis]
69 Sim JH, Sherman JB, Stanley TL, Corey KE, Fitch KV, Looby SE, Robinson JA, Lu MT, Burdo TH, Lo J. Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection. AIDS Res Hum Retroviruses 2021;37:385-90. [PMID: 33323025 DOI: 10.1089/AID.2020.0177] [Reference Citation Analysis]
70 Veracruz N, Hameed B, Saab S, Wong RJ. The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. J Clin Exp Hepatol 2021;11:45-81. [PMID: 33679048 DOI: 10.1016/j.jceh.2020.04.018] [Reference Citation Analysis]
71 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
72 Shah RA, Kowdley KV. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2020;14:311-321. [PMID: 32241197 DOI: 10.1080/17474124.2020.1748498] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
73 Narayanan S, Surette FA, Hahn YS. The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw 2016;16:147-58. [PMID: 27340383 DOI: 10.4110/in.2016.16.3.147] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
74 Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K, Clouston AD. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393-1405. [PMID: 24254368 DOI: 10.1002/hep.26937] [Cited by in Crossref: 197] [Cited by in F6Publishing: 186] [Article Influence: 24.6] [Reference Citation Analysis]
75 Yang J, Chang N, Yang L, Ji X, Zhou X, Tian L, Ma Y, Yang Y, Liu Y, Yang L, Li L. Sphingosine 1-Phosphate Receptor Blockade Affects Pro-Inflammatory Bone Marrow-Derived Macrophages and Relieves Mouse Fatty Liver Injury. Int J Mol Sci 2019;20:E4695. [PMID: 31546702 DOI: 10.3390/ijms20194695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
76 Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, Zafonte R, Cabibi D, Cammà C, Di Marco V, Licata A, Magliozzo F, Marchesini G, Merlino G, Craxì A, Pinto A. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol 2018;17:28. [PMID: 29452601 DOI: 10.1186/s12933-018-0670-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
77 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 372] [Cited by in F6Publishing: 347] [Article Influence: 28.6] [Reference Citation Analysis]
78 Sun SM, Wang YY, Zhang Q, Liu L, Meng G, Yao ZX, Wu HM, Xia Y, Bao X, Gu YQ, Wang HL, Shi HB, Xu HY, Wang X, Zhou M, Jiao HL, Jia QY, Wang BM, Niu KJ. Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease: Serum immunoglobulins and NAFLD. Journal of Digestive Diseases 2018;19:498-507. [DOI: 10.1111/1751-2980.12646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Shao J, Zeng S, Zhou B, Xu H, Bian Y, Xu Y. Angiogenic factor with G patch and FHA domains 1 (Aggf1) promotes hepatic steatosis in mice. Biochem Biophys Res Commun 2017;482:134-40. [PMID: 27865839 DOI: 10.1016/j.bbrc.2016.10.071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Dorn C, Kraus B, Motyl M, Weiss TS, Gehrig M, Schölmerich J, Heilmann J, Hellerbrand C. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res 2010;54 Suppl 2:S205-13. [PMID: 20087858 DOI: 10.1002/mnfr.200900314] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
81 Zhu D, Su Y, Zheng Y, Fu B, Tang L, Qin YX. Zinc regulates vascular endothelial cell activity through zinc-sensing receptor ZnR/GPR39. Am J Physiol Cell Physiol 2018;314:C404-14. [PMID: 29351417 DOI: 10.1152/ajpcell.00279.2017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
82 Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, Wu T, George J, McCaughan GW, Twigg SM. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.J Diabetes Complications. 2015;29:1240-1247. [PMID: 26297218 DOI: 10.1016/j.jdiacomp.2015.06.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
83 Ariz U, Mato JM, Lu SC, Martínez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods Mol Biol. 2010;593:109-136. [PMID: 19957147 DOI: 10.1007/978-1-60327-194-3_6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
84 Sigrist-Flores SC, Ponciano-Gómez A, Pedroza-González A, Gallardo-Ortíz IA, Villalobos-Molina R, Pardo-Vázquez JP, Saucedo-Campos AD, Jiménez-Flores R, Méndez-Cruz AR. Chronic intake of moderate fat-enriched diet induces fatty liver and low-grade inflammation without obesity in rabbits. Chem Biol Interact 2019;300:56-62. [PMID: 30639268 DOI: 10.1016/j.cbi.2019.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
85 Amirkalali B, Sohrabi MR, Esrafily A, Jalali M, Gholami A, Hosseinzadeh P, Keyvani H, Shidfar F, Zamani F. Erythrocyte membrane fatty acid profile & serum cytokine levels in patients with non-alcoholic fatty liver disease. Indian J Med Res 2018;147:352-60. [PMID: 29998870 DOI: 10.4103/ijmr.IJMR_1065_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
86 Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18(8): 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727] [Cited by in CrossRef: 193] [Cited by in F6Publishing: 177] [Article Influence: 19.3] [Reference Citation Analysis]
87 Haentjens P, Massaad D, Reynaert H, Peeters E, Van Meerhaeghe A, Vinken S, Poppe K, Velkeniers B. IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS. Acta Clinica Belgica 2014;64:483-93. [DOI: 10.1179/acb.2009.084] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
88 Constantinescu C, SĂndulescu L, SĂftoiu A. The Role of Elastography in Non-Alcoholic Fatty Liver Disease. Curr Health Sci J 2020;46:255-69. [PMID: 33304627 DOI: 10.12865/CHSJ.46.03.07] [Reference Citation Analysis]
89 Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594. e1. [PMID: 25066692 DOI: 10.1053/j.gastro.2014.06.043] [Cited by in Crossref: 406] [Cited by in F6Publishing: 399] [Article Influence: 50.8] [Reference Citation Analysis]
90 Amano Y, Tsuchiya S, Imai M, Tohyama K, Matsukawa J, Isono O, Yasuno H, Enya K, Koumura E, Nagabukuro H. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochemical and Biophysical Research Communications 2018;497:207-13. [DOI: 10.1016/j.bbrc.2018.02.055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Picardi A, Vespasiani-gentilucci U. Association Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A First Message Should Pass. The American Journal of Gastroenterology 2008;103:3036-8. [DOI: 10.1111/j.1572-0241.2008.02196.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
92 Liu B, Xiang L, Ji J, Liu W, Chen Y, Xia M, Liu Y, Liu W, Zhu P, Jin Y, Han Y, Lu J, Li X, Zheng M, Lu Y. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021;131:e144801. [PMID: 34651580 DOI: 10.1172/JCI144801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Wang YL, Liu LJ, Zhao WH, Li JX. Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med. 2015;2015:715638. [PMID: 26221176 DOI: 10.1155/2015/715638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
94 Guo J, Wang C, Guo Z, Zuo Z. Exposure to environmental level phenanthrene induces a NASH-like phenotype in new born rat. Environmental Pollution 2018;239:261-71. [DOI: 10.1016/j.envpol.2018.04.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
95 Kim YJ, Choi MS, Park YB, Kim SR, Lee MK, Jung UJ. Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol 2013; 19(29): 4689-4701 [PMID: 23922466 DOI: 10.3748/wjg.v19.i29.4689] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
96 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
97 Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm Bowel Dis 2021:izab199. [PMID: 34374782 DOI: 10.1093/ibd/izab199] [Reference Citation Analysis]
98 Maung K, Ramalingam S, Chaudhry M, Ren Y, Jung SH, Romero K, Corbet K, Chao NJ, Choi T, Diehl AM, Diehl L, Gasparetto C, Horwitz M, Long GD, Lopez RD, Rizzieri DA, Sarantopoulos S, Sullivan KM, Bashir MR, Sung AD. Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS One 2020;15:e0238824. [PMID: 32915853 DOI: 10.1371/journal.pone.0238824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:365-85. [PMID: 27063275 DOI: 10.1016/j.cld.2015.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
100 Bekaert M, Ouwens DM, Hörbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, Geerts A, Verhelst X, Kaufman J, Lapauw B. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity: Chemerin Expression in Patients with NAFLD. Obesity 2016;24:2544-52. [DOI: 10.1002/oby.21674] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
101 Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34289181 DOI: 10.1111/jgh.15631] [Reference Citation Analysis]
102 Ghosh Dastidar S, Jagatheesan G, Haberzettl P, Shah J, Hill BG, Bhatnagar A, Conklin DJ. Glutathione S-transferase P deficiency induces glucose intolerance via JNK-dependent enhancement of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2018;315:E1005-18. [PMID: 30153066 DOI: 10.1152/ajpendo.00345.2017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
103 Akinkugbe AA, Avery CL, Barritt AS, Cole SR, Lerch M, Mayerle J, Offenbacher S, Petersmann A, Nauck M, Völzke H, Slade GD, Heiss G, Kocher T, Holtfreter B. Do Genetic Markers of Inflammation Modify the Relationship between Periodontitis and Nonalcoholic Fatty Liver Disease? Findings from the SHIP Study. J Dent Res 2017;96:1392-9. [PMID: 28732187 DOI: 10.1177/0022034517720924] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
104 He Y, Li W, Li Y, Zhang S, Wang Y, Sun C. Ursolic acid increases glucose uptake through the PI3K signaling pathway in adipocytes. PLoS One. 2014;9:e110711. [PMID: 25329874 DOI: 10.1371/journal.pone.0110711] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
105 Kajikawa S, Imada K, Takeuchi T, Shimizu Y, Kawashima A, Harada T, Mizuguchi K. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. Dig Dis Sci. 2011;56:1065-1074. [PMID: 20848203 DOI: 10.1007/s10620-010-1400-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
106 Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287:40161-40172. [PMID: 23066023 DOI: 10.10747/jbc.M112.417014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Bhathena J, Martoni C, Kulamarva A, Tomaro-Duchesneau C, Malhotra M, Paul A, Urbanska AM, Prakash S. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters. PLoS One. 2013;8:e58394. [PMID: 23554890 DOI: 10.1371/journal.pone.0058394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
108 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 2012;52:59-69. [DOI: 10.1016/j.freeradbiomed.2011.10.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 519] [Article Influence: 53.9] [Reference Citation Analysis]
109 Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology 2017;65:853-63. [PMID: 27981599 DOI: 10.1002/hep.28968] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
110 Meng Q, Duan Z, Lin Z, Yu H, Li J, Liu Y. Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C. Dig Dis Sci 2009;54:1120-7. [DOI: 10.1007/s10620-008-0455-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Oates JR, McKell MC, Moreno-Fernandez ME, Damen MSMA, Deepe GS Jr, Qualls JE, Divanovic S. Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack. Front Immunol 2019;10:2893. [PMID: 31921154 DOI: 10.3389/fimmu.2019.02893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
112 Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372-1379. [PMID: 18510618 DOI: 10.1111/j.1572-0241.2007.01774.x] [Cited by in Crossref: 356] [Cited by in F6Publishing: 356] [Article Influence: 25.4] [Reference Citation Analysis]
113 Hu Y, Liu X. Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology 2009;44:1356-62. [DOI: 10.3109/00365520903312441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
114 Han H, Ma H, Rong S, Chen L, Shan Z, Xu J, Zhang Y, Liu L. Flaxseed oil containing flaxseed oil ester of plant sterol attenuates high-fat diet-induced hepatic steatosis in apolipoprotein-E knockout mice. Journal of Functional Foods 2015;13:169-82. [DOI: 10.1016/j.jff.2014.12.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
115 Haque JA, McMahan RS, Campbell JS, Shimizu-Albergine M, Wilson AM, Botta D, Bammler TK, Beyer RP, Montine TJ, Yeh MM, Kavanagh TJ, Fausto N. Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab Invest 2010;90:1704-17. [PMID: 20548286 DOI: 10.1038/labinvest.2010.112] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
116 Aller MA, Arias JL, Cruz A, Arias J. Inflammation: a way to understanding the evolution of portal hypertension. Theor Biol Med Model 2007;4:44. [PMID: 17999758 DOI: 10.1186/1742-4682-4-44] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
117 Galastri S, Zamara E, Milani S, Novo E, Provenzano A, Delogu W, Vizzutti F, Sutti S, Locatelli I, Navari N. Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond). 2012;123:459-471. [PMID: 22545719 DOI: 10.1042/cs20110515] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
118 Baeza-Raja B, Goodyear A, Liu X, Lam K, Yamamoto L, Li Y, Dodson GS, Takeuchi T, Kisseleva T, Brenner DA, Dabbagh K. Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. PLoS One 2020;15:e0234038. [PMID: 32492075 DOI: 10.1371/journal.pone.0234038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
119 Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16:1394-1399. [PMID: 18369343 DOI: 10.1038/oby.2008.64] [Cited by in Crossref: 127] [Cited by in F6Publishing: 133] [Article Influence: 9.1] [Reference Citation Analysis]
120 Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
121 Bordignon M, Viel G, Peserico A, Alaibac M. Non-alcoholic fatty liver disease, alcohol intake and psoriasis. J Hepatol. 2010;53:587. [PMID: 20561701 DOI: 10.1016/j.jhep.2010.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
122 Tell G, Vascotto C, Tiribelli C. Alterations in the redox state and liver damage: hints from the EASL Basic School of Hepatology. J Hepatol 2013;58:365-74. [PMID: 23023012 DOI: 10.1016/j.jhep.2012.09.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
123 Yaghooti H, Mohammadtaghvaei N, Mahboobnia K. Effects of palmitate and astaxanthin on cell viability and proinflammatory characteristics of mesenchymal stem cells. Int Immunopharmacol 2019;68:164-70. [PMID: 30639962 DOI: 10.1016/j.intimp.2018.12.063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
124 Harada PH, Bensenõr IJM, Drager LF, Goulart AC, Mill JG, Lotufo PA. Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. Atherosclerosis 2019;284:59-65. [PMID: 30875494 DOI: 10.1016/j.atherosclerosis.2019.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
125 Xie M, Tang H, Li F, Wu S, Dong Y, Yang Y, Baker JS, Ma J. Mediating Roles of hsCRP, TNF-α and Adiponectin on the Associations between Body Fat and Fatty Liver Disease among Overweight and Obese Adults. Biology (Basel) 2021;10:895. [PMID: 34571772 DOI: 10.3390/biology10090895] [Reference Citation Analysis]
126 Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 2012;166:503-10. [PMID: 22170794 DOI: 10.1530/EJE-11-0864] [Cited by in Crossref: 107] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
127 Sendi H, Mead I, Wan M, Mehrab-Mohseni M, Koch K, Atala A, Bonkovsky HL, Bishop CE. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS One. 2018;13:e0200847. [PMID: 30024933 DOI: 10.1371/journal.pone.0200847] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
128 Zou A, Magee N, Deng F, Lehn S, Zhong C, Zhang Y. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. J Biol Chem 2018;293:8656-71. [PMID: 29666185 DOI: 10.1074/jbc.RA117.001653] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
129 Ko JS. Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2010;56:6. [DOI: 10.4166/kjg.2010.56.1.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
130 Woo J, Shin KO, Yoo JH, Park S, Kang S. The effects of detraining on blood adipokines and antioxidant enzyme in Korean overweight children. Eur J Pediatr. 2012;171:235-243. [PMID: 21701811 DOI: 10.1007/s00431-011-1518-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
131 Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, Long MT. Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clin Gastroenterol Hepatol 2019; 17: 1157-1164. e4. [PMID: 30476583 DOI: 10.1016/j.cgh.2018.11.037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
132 Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, Mazzocca A. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res 2021;198:139-50. [PMID: 33340925 DOI: 10.1016/j.thromres.2020.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72-81. [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003] [Cited by in Crossref: 293] [Cited by in F6Publishing: 288] [Article Influence: 20.9] [Reference Citation Analysis]
134 States JC, Srivastava S, Chen Y, Barchowsky A. Arsenic and cardiovascular disease. Toxicol Sci 2009;107:312-23. [PMID: 19015167 DOI: 10.1093/toxsci/kfn236] [Cited by in Crossref: 198] [Cited by in F6Publishing: 188] [Article Influence: 14.1] [Reference Citation Analysis]
135 Pan MH, Lai CS, Tsai ML, Ho CT. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 2014;58:147-171. [PMID: 24302567 DOI: 10.1002/mnfr.201300522] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
136 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
137 Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B. Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2010;95:3039-47. [DOI: 10.1210/jc.2009-2148] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
138 Yu CJ, Wang QS, Wu MM, Song BL, Liang C, Lou J, Tang LL, Yu XD, Niu N, Yang X, Zhang BL, Qu Y, Liu Y, Dong ZC, Zhang ZR. TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice. Hepatology 2018;68:1769-85. [PMID: 29704259 DOI: 10.1002/hep.30066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
139 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
140 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
141 Pathak R, Kumar A, Palfrey HA, Forney LA, Stone KP, Raju NR, Gettys TW, Murthy SN. The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet. Inflamm Res 2019;68:581-95. [PMID: 31073849 DOI: 10.1007/s00011-019-01243-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. The American Journal of Clinical Nutrition 2007;86:285-300. [DOI: 10.1093/ajcn/86.2.285] [Cited by in Crossref: 256] [Cited by in F6Publishing: 236] [Article Influence: 17.1] [Reference Citation Analysis]
143 Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. Journal of Hepatology 2006;45:879-81. [DOI: 10.1016/j.jhep.2006.09.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
144 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Lee YH, Wu YJ, Liu CC, Hou CJ, Yeh HI, Tsai CH, Shih SC, Hung CL. The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification. Radiol Res Pract. 2011;2011:586785. [PMID: 22254139 DOI: 10.1155/2011/586785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
146 Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28:200-208. [PMID: 18445142 DOI: 10.1111/j.1365-2036.2008.03723.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
147 Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol. 2012;181:1287-1295. [PMID: 22841818 DOI: 10.1016/j.ajpath.2012.06.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
148 Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, Coskunpinar E, Kahraman OT, Mesci B, Ulasoglu C. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013;43:100-107. [PMID: 22661277 DOI: 10.1007/s12020-012-9712-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
149 Nawaz R, Zahid S, Idrees M, Rafique S, Shahid M, Ahad A, Amin I, Almas I, Afzal S. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis. Inflamm Res 2017;66:477-86. [PMID: 28285394 DOI: 10.1007/s00011-017-1029-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
150 Kołodziejski PA, Pruszyńska-oszmałek E, Strowski MZ, Nowak KW. Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function. Endocrine 2017;56:538-50. [DOI: 10.1007/s12020-017-1309-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
151 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 231] [Article Influence: 24.7] [Reference Citation Analysis]
152 Cynis H, Kehlen A, Haegele M, Hoffmann T, Heiser U, Fujii M, Shibazaki Y, Yoneyama H, Schilling S, Demuth HU. Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol 2013;94:217-25. [PMID: 23560443 DOI: 10.1111/iep.12020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
153 Lee TI, Kao YH, Baigalmaa L, Lee TW, Lu YY, Chen YC, Chao TF, Chen YJ. Sodium hydrosulphide restores tumour necrosis factor-α-induced mitochondrial dysfunction and metabolic dysregulation in HL-1 cells. J Cell Mol Med 2019;23:7641-50. [PMID: 31496037 DOI: 10.1111/jcmm.14637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
154 Uto H. alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease. Hepatol Res 2009;39:845-6. [PMID: 19712270 DOI: 10.1111/j.1872-034X.2009.00585.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Xu C, Wang G, Hao Y, Zhi J, Zhang L, Chang C. Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver. Dig Dis Sci. 2011;56:2299-2308. [PMID: 21327921 DOI: 10.1007/s10620-011-1599-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
156 Miele L, Alberelli MA, Martini M, Liguori A, Marrone G, Cocomazzi A, Vecchio FM, Landolfi R, Gasbarrini A, Grieco A, De Candia E. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res 2021;231:24-38. [PMID: 33171266 DOI: 10.1016/j.trsl.2020.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
157 Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, Batur Y. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2009;9:16. [PMID: 19222849 DOI: 10.1186/1471-230x-9-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
158 Hosseinpour-arjmand S, Amirkhizi F, Ebrahimi-mameghani M. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2019;44:258-67. [DOI: 10.1111/jcpt.12784] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
159 Li J, Chanda D, van Gorp PJ, Jeurissen ML, Houben T, Walenbergh SM, Debets J, Oligschlaeger Y, Gijbels MJ, Neumann D, Shiri-Sverdlov R. Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS One 2016;11:e0163843. [PMID: 27685150 DOI: 10.1371/journal.pone.0163843] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
160 Schwartz JJ, Emerson L, Hillas E, Phan A, Thiesset H, Firpo M, Sorensen J, Kennedy T, Rinella M. Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative. Hepatol Int 2013;7:600-9. [PMID: 26201793 DOI: 10.1007/s12072-013-9426-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
161 Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol. 2011;55:660-665. [PMID: 21238518 DOI: 10.1016/j.jhep.2010.12.017] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 5.0] [Reference Citation Analysis]
162 Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic Fatty liver disease: an overview. J Genet Genomics. 2013;40:15-22. [PMID: 23357341 DOI: 10.1016/j.jgg.2012.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
163 Fontes-Cal TCM, Mattos RT, Medeiros NI, Pinto BF, Belchior-Bezerra M, Roque-Souza B, Dutra WO, Ferrari TCA, Vidigal PVT, Faria LC, Couto CA, Gomes JAS. Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Front Immunol 2021;12:708959. [PMID: 34447378 DOI: 10.3389/fimmu.2021.708959] [Reference Citation Analysis]
164 Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi PJ, Tiribelli C, Rosso N. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients 2017;9:E1006. [PMID: 28895929 DOI: 10.3390/nu9091006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
165 Hu YB. Mechanisms of non-alcoholic steatohepatitis: pathophysiology and molecular biology. Shijie Huaren Xiaohua Zazhi 2009; 17(13): 1329-1334 [DOI: 10.11569/wcjd.v17.i13.1329] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
166 Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Annals of Hepatology 2009;8:S25-33. [DOI: 10.1016/s1665-2681(19)31823-x] [Cited by in Crossref: 27] [Article Influence: 2.1] [Reference Citation Analysis]
167 Sanal MG. The blind men ‘see’ the elephant-the many faces of fatty liver disease. World J Gastroenterol 2008; 14(6): 831-844 [PMID: 18240340 DOI: 10.3748/wjg.14.831] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
168 Erbaş O, Akseki HS, Solmaz V, Aktuğ H, Taşkıran D. Fatty liver-induced changes in stereotypic behavior in rats and effects of glucagon-like peptide-1 analog on stereotypy. The Kaohsiung Journal of Medical Sciences 2014;30:447-52. [DOI: 10.1016/j.kjms.2014.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Woo CWH, Siow YL, O K. Homocysteine induces monocyte chemoattractant protein-1 expression in hepatocytes mediated via activator protein-1 activation. J Biol Chem 2008;283:1282-92. [PMID: 18024959 DOI: 10.1074/jbc.M707886200] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
170 Matthew Morris E, Fletcher JA, Thyfault JP, Scott Rector R. The role of angiotensin II in nonalcoholic steatohepatitis. Molecular and Cellular Endocrinology 2013;378:29-40. [DOI: 10.1016/j.mce.2012.04.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
171 Lee SP. Non-Alcoholic Fatty Liver Disease, a Marker of Subclinical Atherosclerosis Applicable Only to Metabolic Syndrome?: Time to Organize the Connection between Metabolism and Atherosclerosis. J Cardiovasc Ultrasound 2012;20:124-5. [PMID: 23185654 DOI: 10.4250/jcu.2012.20.3.124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
172 Han S, Zhu F, Huang X, Yan P, Xu K, Shen F, Sun J, Yang Z, Jin G, Teng Y. Maternal obesity accelerated non-alcoholic fatty liver disease in offspring mice by reducing autophagy. Exp Ther Med 2021;22:716. [PMID: 34007325 DOI: 10.3892/etm.2021.10148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Boga S, Koksal AR, Alkim H, Yilmaz Ozguven MB, Bayram M, Ergun M, Sisman G, Tekin Neijmann S, Alkim C. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metab Syndr Relat Disord. 2015;13:393-399. [PMID: 26367098 DOI: 10.1089/met.2015.0046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
174 Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012;56:1363-1370. [PMID: 22314419 DOI: 10.1016/j.jhep.2011.12.025] [Cited by in Crossref: 141] [Cited by in F6Publishing: 121] [Article Influence: 14.1] [Reference Citation Analysis]
175 Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P. Activin A in Nonalcoholic Fatty Liver Disease. Activins and Inhibins. Elsevier; 2011. pp. 323-42. [DOI: 10.1016/b978-0-12-385961-7.00015-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
176 Zou X, Yan C, Shi Y, Cao K, Xu J, Wang X, Chen C, Luo C, Li Y, Gao J, Pang W, Zhao J, Zhao F, Li H, Zheng A, Sun W, Long J, Szeto IM, Zhao Y, Dong Z, Zhang P, Wang J, Lu W, Zhang Y, Liu J, Feng Z. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. Antioxid Redox Signal 2014;21:1557-70. [PMID: 24393106 DOI: 10.1089/ars.2013.5538] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 8.5] [Reference Citation Analysis]
177 Armstrong LE, Guo GL. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr Pharmacol Rep 2017;3:92-100. [PMID: 28983452 DOI: 10.1007/s40495-017-0085-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
178 Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240. [PMID: 16970951 DOI: 10.1016/j.atherosclerosis.2006.08.021] [Cited by in Crossref: 355] [Cited by in F6Publishing: 328] [Article Influence: 22.2] [Reference Citation Analysis]
179 Xu L, Chen Y, Nagashimada M, Ni Y, Zhuge F, Chen G, Li H, Pan T, Yamashita T, Mukaida N, Kaneko S, Ota T, Nagata N. CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. Metabolism 2021;125:154914. [PMID: 34656648 DOI: 10.1016/j.metabol.2021.154914] [Reference Citation Analysis]
180 De Oliveira Cipriano Torres D, Dos Santos ACO, Silva AKSE, Leite JIA, De Souza JRB, Beltrão EIC, Peixoto CA. Effect of maternal diet rich in omega-6 and omega-9 fatty acids on the liver of LDL receptor-deficient mouse offspring. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2010;89:164-70. [DOI: 10.1002/bdrb.20240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
181 Brempelis KJ, Crispe IN. Infiltrating monocytes in liver injury and repair. Clin Transl Immunology 2016;5:e113. [PMID: 27990288 DOI: 10.1038/cti.2016.62] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
182 Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2:1344-1355. [PMID: 30411081 DOI: 10.1002/hep4.1237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
183 Velázquez KT, Enos RT, Bader JE, Sougiannis AT, Carson MS, Chatzistamou I, Carson JA, Nagarkatti PS, Nagarkatti M, Murphy EA. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World J Hepatol 2019; 11(8): 619-637 [PMID: 31528245 DOI: 10.4254/wjh.v11.i8.619] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
184 Jiménez-Castro MB, Casillas-Ramírez A, Negrete-Sánchez E, Avalos-de León CG, Gracia-Sancho J, Peralta C. Adipocytokines in Steatotic Liver Surgery/Transplantation. Transplantation 2019;103:71-7. [PMID: 30586349 DOI: 10.1097/TP.0000000000002098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
185 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. The pro-inflammatory action of tumour necrosis factor-α in non-alcoholic steatohepatitis is independent of the NSMAF gene product. Dig Liver Dis 2013;45:147-54. [PMID: 23044079 DOI: 10.1016/j.dld.2012.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
186 Takai A, Kikuchi K, Kajiyama Y, Sugiura A, Negishi M, Tsunashima H, Yamada H, Matsumoto K, Tsuneyama K, Moritoki Y, Hara M, Miyakawa H. Serological and Histological Examination of a Nonalcoholic Steatohepatitis Mouse Model Created via the Administration of Monosodium Glutamate. Int Sch Res Notices 2014;2014:725351. [PMID: 27433515 DOI: 10.1155/2014/725351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
187 Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism. 2015;64:60-78. [PMID: 25456097 DOI: 10.1016/j.metabol.2014.10.012] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 13.5] [Reference Citation Analysis]
188 Li X, Cheng X, Wang X, Liu Q, Ma H, Li M. Dyslipidemic Diet Induces Mobilization of Peripheral Neutrophils and Monocytes That Exacerbate Hemorrhagic Brain Injury and Neuroinflammation. Front Cell Neurosci 2020;14:154. [PMID: 32655370 DOI: 10.3389/fncel.2020.00154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
189 Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, Hirose H, Ito M, Ishihara A, Iwaasa H. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res. 2007;37:50-57. [PMID: 17300698 DOI: 10.1111/j.1872-034x.2007.00008.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 75] [Article Influence: 11.8] [Reference Citation Analysis]
190 Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-järvinen H. Gene expression in human NAFLD. American Journal of Physiology-Gastrointestinal and Liver Physiology 2008;294:G1281-7. [DOI: 10.1152/ajpgi.00074.2008] [Cited by in Crossref: 242] [Cited by in F6Publishing: 244] [Article Influence: 17.3] [Reference Citation Analysis]
191 van 't Erve TJ, Kadiiska MB, London SJ, Mason RP. Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis. Redox Biol 2017;12:582-99. [PMID: 28391180 DOI: 10.1016/j.redox.2017.03.024] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 15.4] [Reference Citation Analysis]
192 Giustarini D, Dalle-donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. Critical Reviews in Clinical Laboratory Sciences 2009;46:241-81. [DOI: 10.3109/10408360903142326] [Cited by in Crossref: 273] [Cited by in F6Publishing: 244] [Article Influence: 21.0] [Reference Citation Analysis]
193 Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, Chayama K. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43:298-304. [PMID: 18458846 DOI: 10.1007/s00535-007-2152-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
194 Hamaguchi M, Okamura T, Fukuda T, Nishida K, Yoshimura Y, Hashimoto Y, Ushigome E, Nakanishi N, Majima S, Asano M, Yamazaki M, Takakuwa H, Kita M, Fukui M. Group 3 Innate Lymphoid Cells Protect Steatohepatitis From High-Fat Diet Induced Toxicity. Front Immunol 2021;12:648754. [PMID: 33790913 DOI: 10.3389/fimmu.2021.648754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
195 Ramadori P, Kroy D, Streetz KL. Immunoregulation by lipids during the development of non-alcoholic steatohepatitis. Hepatobiliary Surg Nutr 2015;4:11-23. [PMID: 25713801 DOI: 10.3978/j.issn.2304-3881.2015.01.02] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
196 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
197 Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-91. [PMID: 19896127 DOI: 10.1016/j.atherosclerosis.2009.10.011] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
198 Prisingkorn W, Prathomya P, Jakovlić I, Liu H, Zhao YH, Wang WM. Transcriptomics, metabolomics and histology indicate that high-carbohydrate diet negatively affects the liver health of blunt snout bream (Megalobrama amblycephala). BMC Genomics 2017;18:856. [PMID: 29121861 DOI: 10.1186/s12864-017-4246-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
199 Bonelli F, Meucci V, Divers TJ, Wagner B, Intorre L, Sgorbini M. Kinetics of plasma procalcitonin, soluble CD14, CCL2 and IL-10 after a sublethal infusion of lipopolysaccharide in horses. Vet Immunol Immunopathol 2017;184:29-35. [PMID: 28166929 DOI: 10.1016/j.vetimm.2016.12.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
200 Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49:595-599. [PMID: 18662837 DOI: 10.1016/j.jhep.2008.05.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
201 Orlicky DJ, Libby AE, Bales ES, McMahan RH, Monks J, La Rosa FG, McManaman JL. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions. J Physiol 2019;597:1565-84. [PMID: 30536914 DOI: 10.1113/JP277140] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
202 Rabbani N, Xue M, Thornalley PJ. Dicarbonyl stress, protein glycation and the unfolded protein response. Glycoconj J 2021;38:331-40. [PMID: 33644826 DOI: 10.1007/s10719-021-09980-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
203 Rafie R, Hosseini SA, Hajiani E, Saki Malehi A, Mard SA. Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Clin Exp Gastroenterol 2020;13:35-45. [PMID: 32158249 DOI: 10.2147/CEG.S234698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
204 Yin X, Peng J, Zhao L, Yu Y, Zhang X, Liu P, Feng Q, Hu Y, Pang X. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst Appl Microbiol. 2013;36:188-196. [PMID: 23453736 DOI: 10.1016/j.syapm.2012.12.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
205 Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011;41:911-920. [PMID: 21951869 DOI: 10.1111/j.1872-034x.2011.00867.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
206 Chen Z, Liu F, Zheng N, Guo M, Bao L, Zhan Y, Zhang M, Zhao Y, Guo W, Ding G. Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development. Biomed Pharmacother 2019;110:285-93. [PMID: 30522014 DOI: 10.1016/j.biopha.2018.11.069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
207 Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020;20:40-54. [DOI: 10.1038/s41577-019-0198-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 59.7] [Reference Citation Analysis]
208 Sharifi N, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? Endocrine. 2014;47:70-80. [PMID: 24968737 DOI: 10.1007/s12020-014-0336-5] [Cited by in Crossref: 136] [Cited by in F6Publishing: 122] [Article Influence: 17.0] [Reference Citation Analysis]
209 Kotronen A, Yki-järvinen H. Fatty Liver: A Novel Component of the Metabolic Syndrome. ATVB 2008;28:27-38. [DOI: 10.1161/atvbaha.107.147538] [Cited by in Crossref: 541] [Cited by in F6Publishing: 251] [Article Influence: 38.6] [Reference Citation Analysis]
210 Kar S, Paglialunga S, Jaycox SH, Islam R, Paredes AH. Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. PLoS One 2019;14:e0217263. [PMID: 31291245 DOI: 10.1371/journal.pone.0217263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
211 Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem 2011;44:1375-9. [PMID: 22015687 DOI: 10.1016/j.clinbiochem.2011.09.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
212 Ferrandino G, Orf I, Smith R, Calcagno M, Thind AK, Debiram-Beecham I, Williams M, Gandelman O, de Saedeleer A, Kibble G, Lydon AM, Mayhew CA, Allsworth M, Boyle B, van der Schee MP, Allison M, Hoare M, Snowdon VK. Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound-Toward Improved Detection of Liver Impairment. Clin Transl Gastroenterol 2020;11:e00239. [PMID: 33094960 DOI: 10.14309/ctg.0000000000000239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
213 Yndestad A, Haukeland JW, Dahl TB, Bjøro K, Gladhaug IP, Berge C, Damås JK, Haaland T, Løberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol 2009;104:2196-205. [PMID: 19532130 DOI: 10.1038/ajg.2009.318] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
214 Wu L, Gao X, Guo Q, Li J, Yao J, Yan K, Xu Y, Jiang X, Ye D, Guo J. The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise. Hepatol Int 2020;14:652-66. [PMID: 32880077 DOI: 10.1007/s12072-020-10081-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
215 Gungor S, Köylü AA, Saglam S, Neselioglu S, Erel Ö, Acıpayam C. Effects of Oxidant-Antioxidant and Vitamin D Levels on Clinical and Laboratory Data in Children With Fatty Liver Disease. Cureus 2020;12:e11849. [PMID: 33282605 DOI: 10.7759/cureus.11849] [Reference Citation Analysis]
216 Mills EL, Harmon C, Jedrychowski MP, Xiao H, Garrity R, Tran NV, Bradshaw GA, Fu A, Szpyt J, Reddy A, Prendeville H, Danial NN, Gygi SP, Lynch L, Chouchani ET. UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab 2021;3:604-17. [PMID: 34002097 DOI: 10.1038/s42255-021-00389-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
217 Feehan J, Tripodi N, Fraser S, Mikkelsen K, Thewlis A, Kiatos D, Husaric M, Apostolopoulos V. Polarized light therapy: Shining a light on the mechanism underlying its immunomodulatory effects. J Biophotonics 2020;13:e201960177. [PMID: 31816155 DOI: 10.1002/jbio.201960177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
218 Kim HM, Kim YM, Huh JH, Lee ES, Kwon MH, Lee BR, Ko HJ, Chung CH. α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition C-C chemokine receptor 2. PLoS One 2017;12:e0179204. [PMID: 28598982 DOI: 10.1371/journal.pone.0179204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
219 Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, Lykkesfeldt J, Fledelius C. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 2018;10:4. [PMID: 29410708 DOI: 10.1186/s13098-018-0307-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
220 Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS. Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS One. 2013;8:e49286. [PMID: 23326306 DOI: 10.1371/journal.pone.0049286] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
221 Chen YJ, Wallig MA, Jeffery EH. Dietary Broccoli Lessens Development of Fatty Liver and Liver Cancer in Mice Given Diethylnitrosamine and Fed a Western or Control Diet. J Nutr 2016;146:542-50. [PMID: 26865652 DOI: 10.3945/jn.115.228148] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
222 Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther. 2010;23:155-159. [PMID: 20415823 DOI: 10.1111/j.1529-8019.2010.01310.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
223 Muto H, Ito T, Tanaka T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Maeda K, Honda T, Ishikawa T, Kato A, Ohshiro T, Kano F, Yamamoto A, Sakai K, Hibi H, Ishigami M, Fujishiro M. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. Sci Rep 2021;11:18778. [PMID: 34548598 DOI: 10.1038/s41598-021-98254-8] [Reference Citation Analysis]
224 Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221-239. [PMID: 25045276 DOI: 10.2147/ceg.s62831] [Cited by in Crossref: 53] [Cited by in F6Publishing: 114] [Article Influence: 6.6] [Reference Citation Analysis]
225 Lee C, Kim J, Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells 2019;8:E1259. [PMID: 31619023 DOI: 10.3390/cells8101259] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
226 Manco M, Marcellini M, Giannone G, Nobili V. Correlation of Serum TNF-α Levels and Histologic Liver Injury Scores in Pediatric Nonalcoholic Fatty Liver Disease. Am J Clin Pathol 2007;127:954-60. [DOI: 10.1309/6vj4dwgydu0xyj8q] [Cited by in Crossref: 128] [Cited by in F6Publishing: 67] [Article Influence: 8.5] [Reference Citation Analysis]
227 Xiao F, Waldrop SL, Bronk SF, Gores GJ, Davis LS, Kilic G. Lipoapoptosis induced by saturated free fatty acids stimulates monocyte migration: a novel role for Pannexin1 in liver cells. Purinergic Signal. 2015;11:347-359. [PMID: 26054298 DOI: 10.1007/s11302-015-9456-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
228 Faheem SA, Saeed NM, El-Naga RN, Ayoub IM, Azab SS. Hepatoprotective Effect of Cranberry Nutraceutical Extract in Non-alcoholic Fatty Liver Model in Rats: Impact on Insulin Resistance and Nrf-2 Expression. Front Pharmacol 2020;11:218. [PMID: 32256346 DOI: 10.3389/fphar.2020.00218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
229 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
230 Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582-589. [PMID: 17661414 DOI: 10.1002/hep.21768] [Cited by in Crossref: 294] [Cited by in F6Publishing: 282] [Article Influence: 19.6] [Reference Citation Analysis]
231 Pfefferlé M, Ingoglia G, Schaer CA, Yalamanoglu A, Buzzi R, Dubach IL, Tan G, López-Cano EY, Schulthess N, Hansen K, Humar R, Schaer DJ, Vallelian F. Hemolysis transforms liver macrophages into antiinflammatory erythrophagocytes. J Clin Invest 2020;130:5576-90. [PMID: 32663195 DOI: 10.1172/JCI137282] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
232 Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(30): 3945-3954 [PMID: 22912545 DOI: 10.3748/wjg.v18.i30.3945] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
233 Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249-274. [PMID: 26794269 DOI: 10.1038/nrd.2015.3] [Cited by in Crossref: 229] [Cited by in F6Publishing: 222] [Article Influence: 38.2] [Reference Citation Analysis]
234 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
235 Rull A, Rodríguez F, Aragonès G, Marsillach J, Beltrán R, Alonso-villaverde C, Camps J, Joven J. Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine 2009;48:273-9. [DOI: 10.1016/j.cyto.2009.08.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
236 Kuwashiro S, Terai S, Oishi T, Fujisawa K, Matsumoto T, Nishina H, Sakaida I. Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. Cell Tissue Res 2011;344:125-34. [PMID: 21327395 DOI: 10.1007/s00441-011-1132-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
237 Rebelos E, Iozzo P, Guzzardi MA, Brunetto MR, Bonino F. Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease. World J Gastroenterol 2021; 27(30): 4999-5018 [PMID: 34497431 DOI: 10.3748/wjg.v27.i30.4999] [Reference Citation Analysis]
238 Bose T, Alvarenga JC, Tejero ME, Voruganti VS, Proffitt JM, Freeland-Graves JH, Cole SA, Comuzzie AG. Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. J Med Primatol 2009;38:418-24. [PMID: 19702660 DOI: 10.1111/j.1600-0684.2009.00379.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
239 Simon TG, Kartoun U, Zheng H, Chan AT, Chung RT, Shaw S, Corey KE. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun 2017;1:429-38. [PMID: 29085919 DOI: 10.1002/hep4.1051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
240 Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27:301-311. [PMID: 29448843 DOI: 10.1080/13543784.2018.1442436] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
241 Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, Sanyal AJ. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Hepatology 2019;69:1520-34. [PMID: 30394550 DOI: 10.1002/hep.30346] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
242 Camps J, Joven J. Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors. World J Gastroenterol 2015; 21(10): 2875-2882 [PMID: 25780284 DOI: 10.3748/wjg.v21.i10.2875] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
243 Kam TS, Wong CY, Kwan PL, Fat-Yiu W, Chiu SM, Chan SW, Yuen KS, Chan R. Effects and mechanism of turmeric vasorelaxation of the thoracic aorta in hypercholesterolemic rats. J Med Food 2012;15:190-9. [PMID: 22273152 DOI: 10.1089/jmf.2011.1625] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
244 Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42:573-582. [PMID: 17653654 DOI: 10.1007/s00535-007-2060-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 170] [Article Influence: 11.8] [Reference Citation Analysis]
245 Kjærgaard K, Mikkelsen ACD, Wernberg CW, Grønkjær LL, Eriksen PL, Damholdt MF, Mookerjee RP, Vilstrup H, Lauridsen MM, Thomsen KL. Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. J Clin Med 2021;10:673. [PMID: 33572481 DOI: 10.3390/jcm10040673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Song P, Zhang J, Zhang Y, Shu Z, Xu P, He L, Yang C, Zhang J, Wang H, Li Y, Li Q. Hepatic recruitment of CD11b+Ly6C+ inflammatory monocytes promotes hepatic ischemia/reperfusion injury. Int J Mol Med 2018;41:935-45. [PMID: 29251315 DOI: 10.3892/ijmm.2017.3315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
247 Kassel KM, Guo GL, Tawfik O, Luyendyk JP. Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet. Lab Invest. 2010;90:1794-1804. [PMID: 20697377 DOI: 10.1038/labinvest.2010.143] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
248 Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis. Redox Rep. 2013;18:127-133. [PMID: 23743495 DOI: 10.1179/1351000213y.0000000050] [Cited by in Crossref: 66] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
249 Tian W, Xu H, Fang F, Chen Q, Xu Y, Shen A. Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice. Hepatology 2013;58:576-88. [PMID: 23281043 DOI: 10.1002/hep.26207] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 8.8] [Reference Citation Analysis]
250 Chen J, Liang B, Bian D, Luo Y, Yang J, Li Z, Zhuang Z, Zang S, Shi J. Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochemical and Biophysical Research Communications 2019;518:691-7. [DOI: 10.1016/j.bbrc.2019.08.111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
251 Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol 2017;67:801-8. [PMID: 28527666 DOI: 10.1016/j.jhep.2017.05.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
252 Leghi GE, Domenici FA, Vannucchi H. INFLUENCE OF OXIDATIVE STRESS AND OBESITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS. Arq Gastroenterol 2015;52:228-33. [DOI: 10.1590/s0004-28032015000300014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
253 Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
254 Bilgir O, Bilgir F, Bozkaya G, Calan M. Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagulation & Fibrinolysis 2014;25:151-5. [DOI: 10.1097/mbc.0000000000000009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
255 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 197] [Article Influence: 25.3] [Reference Citation Analysis]
256 Bijnen M, van Greevenbroek MMJ, van der Kallen CJH, Scheijen JL, van de Waarenburg MPH, Stehouwer CDA, Wouters K, Schalkwijk CG. Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study. J Diabetes Res 2019;2019:6289831. [PMID: 31218233 DOI: 10.1155/2019/6289831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
257 Wang W, Zhong X, Guo J. Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review). Int J Mol Med 2021;47:114. [PMID: 33907839 DOI: 10.3892/ijmm.2021.4947] [Reference Citation Analysis]
258 Pang Q, Sun Z, Shao C, Cai H, Bao Z, Wang L, Li L, Jing L, Zhang L, Wang Z. CML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver. Front Med (Lausanne) 2020;7:583943. [PMID: 33240906 DOI: 10.3389/fmed.2020.583943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
259 Liu C, Tsai H, Huang C, Tsai C, Su Y, Lin M, Lee K, Hsieh Y, Li T, Huang S, Yang Y, Hou M, Lin H, Lee F, Lee S. Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese rats. American Journal of Physiology-Endocrinology and Metabolism 2018;314:E433-47. [DOI: 10.1152/ajpendo.00094.2017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
260 Moreno Sánchez D. Avances en hígado graso no alcohólico. Medicina Clínica 2009;133:258-60. [DOI: 10.1016/j.medcli.2008.10.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
261 Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758-764. [PMID: 19560226 DOI: 10.1016/j.jhep.2009.04.020] [Cited by in Crossref: 157] [Cited by in F6Publishing: 141] [Article Influence: 12.1] [Reference Citation Analysis]
262 Yilmaz B, Sahin K, Bilen H, Bahcecioglu IH, Bilir B, Ashraf S, Halazun KJ, Kucuk O. Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2015;4:161-171. [PMID: 26151056 DOI: 10.3978/j.issn.2304-3881.2015.01.11] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
263 Chen Y, Chen Y, Zhao L, Chen Y, Mei M, Li Q, Huang A, Varghese Z, Moorhead JF, Ruan XZ. Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export. J Gastroenterol Hepatol. 2012;27:974-984. [PMID: 22098164 DOI: 10.1111/j.1440-1746.2011.06986.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
264 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013;19:5250-69. [PMID: 23394092 DOI: 10.2174/13816128113199990344] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 11.8] [Reference Citation Analysis]
265 Yang SJ, IglayReger HB, Kadouh HC, Bodary PF. Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia. 2009;52:972-981. [PMID: 19277603 DOI: 10.1007/s00125-009-1309-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
266 Matheson PJ, Franklin GA, Hurt RT, Downard CD, Smith JW, Garrison RN. Direct peritoneal resuscitation improves obesity-induced hepatic dysfunction after trauma. J Am Coll Surg 2012;214:517-28; discussion 528-30. [PMID: 22342791 DOI: 10.1016/j.jamcollsurg.2011.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
267 Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. Dig Dis Sci. 2010;55:631-641. [PMID: 19856102 DOI: 10.1007/s10620-009-1020-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
268 Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287:40161-40172. [PMID: 23066023 DOI: 10.1074/jbc.m112.417014] [Cited by in Crossref: 253] [Cited by in F6Publishing: 153] [Article Influence: 25.3] [Reference Citation Analysis]
269 Jeon S, Park Y, Kwon YH. Genistein alleviates the development of nonalcoholic steatohepatitis in ApoE ―/― mice fed a high-fat diet. Mol Nutr Food Res 2014;58:830-41. [DOI: 10.1002/mnfr.201300112] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
270 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-1019. [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021] [Cited by in Crossref: 237] [Cited by in F6Publishing: 203] [Article Influence: 23.7] [Reference Citation Analysis]
271 Yang YM, Wang Z, Matsuda M, Seki E. Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model. Arch Pharm Res 2021;44:230-40. [PMID: 33486695 DOI: 10.1007/s12272-021-01309-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
272 Rabbani N, Xue M, Weickert MO, Thornalley PJ. Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients 2021;13:2374. [PMID: 34371884 DOI: 10.3390/nu13072374] [Reference Citation Analysis]
273 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
274 Kumei S, Yuhki KI, Kojima F, Kashiwagi H, Imamichi Y, Okumura T, Narumiya S, Ushikubi F. Prostaglandin I2 suppresses the development of diet-induced nonalcoholic steatohepatitis in mice. FASEB J 2018;32:2354-65. [PMID: 29247122 DOI: 10.1096/fj.201700590R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
275 Dewhurst MR, Ow JR, Zafer G, van Hul NKM, Wollmann H, Bisteau X, Brough D, Choi H, Kaldis P. Loss of hepatocyte cell division leads to liver inflammation and fibrosis. PLoS Genet 2020;16:e1009084. [PMID: 33147210 DOI: 10.1371/journal.pgen.1009084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
276 Engin A. Non-Alcoholic Fatty Liver Disease. In: Engin AB, Engin A, editors. Obesity and Lipotoxicity. Cham: Springer International Publishing; 2017. pp. 443-67. [DOI: 10.1007/978-3-319-48382-5_19] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 17.0] [Reference Citation Analysis]
277 Scott C, Stokes R, Cha KM, Clouston A, Eslam M, Metwally M, Swarbrick MM, George J, Gunton JE. Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PLoS One. 2019;14:e0225332. [PMID: 31800592 DOI: 10.1371/journal.pone.0225332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
278 Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2011;15:1325-1365. [PMID: 20969475 DOI: 10.1089/ars.2009.3058] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
279 Tazi KA, Quioc JJ, Abdel-Razek W, Tellier Z, Guichard C, Ogier-Denis E, Lebrec D, Moreau R. Protein array technology to investigate cytokine production by monocytes from patients with advanced alcoholic cirrhosis: An ex vivo pilot study. Hepatol Res. 2009;39:706-715. [PMID: 19473436 DOI: 10.1111/j.1872-034x.2009.00498.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
280 Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, Lundbom N, Rissanen A, Lassila R, Yki-Järvinen H. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31:176-183. [PMID: 21134109 DOI: 10.1111/j.1478-3231.2010.02375.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
281 Jang MG, Oh JM, Ko HC, Kim J, Baek S, Jin YJ, Hur S, Kim S. Clerodendrum trichotomum extract improves metabolic derangements in high fructose diet-fed rats. Animal Cells and Systems. [DOI: 10.1080/19768354.2021.2004221] [Reference Citation Analysis]
282 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 95] [Article Influence: 13.8] [Reference Citation Analysis]
283 Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55:1369-1378. [PMID: 22183915 DOI: 10.1002/hep.25531] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
284 Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, Gao L. Hepatic Macrophage as a Key Player in Fatty Liver Disease. Front Immunol 2021;12:708978. [PMID: 34956171 DOI: 10.3389/fimmu.2021.708978] [Reference Citation Analysis]
285 Fan Y, Lu H, Guo Y, Zhu T, Garcia-Barrio MT, Jiang Z, Willer CJ, Zhang J, Chen YE. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. Gastroenterology. 2016;150:1208-1218. [PMID: 26774178 DOI: 10.1053/j.gastro.2016.01.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
286 Roy B, Palaniyandi SS. Tissue-specific role and associated downstream signaling pathways of adiponectin. Cell Biosci 2021;11:77. [PMID: 33902691 DOI: 10.1186/s13578-021-00587-4] [Reference Citation Analysis]
287 Luyendyk JP, Sullivan BP, Guo GL, Wang R. Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. Am J Pathol 2010;176:177-86. [PMID: 20008134 DOI: 10.2353/ajpath.2010.090672] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
288 Patouraux S, Rousseau D, Bonnafous S, Lebeaupin C, Luci C, Canivet CM, Schneck A, Bertola A, Saint-paul M, Iannelli A, Gugenheim J, Anty R, Tran A, Bailly-maitre B, Gual P. CD44 is a key player in non-alcoholic steatohepatitis. Journal of Hepatology 2017;67:328-38. [DOI: 10.1016/j.jhep.2017.03.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
289 Rouvinen-Watt K, Pal C, Martin T, Harris L, Astatkie T, Kryzskaya D, Kärjä V, Mustonen AM, Tammi R, Tammi M, Nieminen P. Evidence of endoplasmic reticulum stress and liver inflammation in the American mink Neovison vison with benign hepatic steatosis. J Comp Physiol B 2014;184:913-27. [PMID: 25079677 DOI: 10.1007/s00360-014-0845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
290 Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017;9:E387. [PMID: 28420094 DOI: 10.3390/nu9040387] [Cited by in Crossref: 166] [Cited by in F6Publishing: 139] [Article Influence: 33.2] [Reference Citation Analysis]
291 Hou C, Wang Y, Zhu E, Yan C, Zhao L, Wang X, Qiu Y, Shen H, Sun X, Feng Z. Coral calcium hydride prevents hepatic steatosis in high fat diet-induced obese rats: A potent mitochondrial nutrient and phase II enzyme inducer. Biochem Pharmacol. 2016;103:85-97. [PMID: 26774456 DOI: 10.1016/j.bcp.2015.12.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
292 Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010;4:623-635. [PMID: 20932147 DOI: 10.1586/egh.10.56] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
293 Jung M, Lee SY, Han SH, Hong J, Na J, Lee JY, Kim Y, Kim S. Hypocholesterolemic effects of Curcuma longa L. with Nelumbo nucifera leaf in an in vitro model and a high cholesterol diet-induced hypercholesterolemic mouse model. Animal Cells and Systems 2015;19:133-43. [DOI: 10.1080/19768354.2014.992953] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
294 Kim CW, Lee CD. Apoptosis and diagnosis of nonalcoholic steatohepatitis. Korean J Hepatol 2011;17:247-9. [PMID: 22102395 DOI: 10.3350/kjhep.2011.17.3.247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
295 Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver International 2009;29:988-96. [DOI: 10.1111/j.1478-3231.2009.02006.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
296 Saeed NM, Mansour AM, Allam S. Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. PharmaNutrition 2020;14:100225. [DOI: 10.1016/j.phanu.2020.100225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Aliasghari F, Izadi A, Jabbari M, Imani B, Gargari BP, Asjodi F, Ebrahimi S. Are Vaspin and Omentin-1 Related to Insulin Resistance, Blood Pressure and Inflammation in NAFLD Patients? J Med Biochem 2018;37:470-5. [PMID: 30584407 DOI: 10.2478/jomb-2018-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
298 Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE; NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 2017;65:65-77. [PMID: 27532276 DOI: 10.1002/hep.28776] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
299 Park JY, Kim Y, Im JA, Lee H. Oligonol suppresses lipid accumulation and improves insulin resistance in a palmitate-induced in HepG2 hepatocytes as a cellular steatosis model. BMC Complement Altern Med. 2015;15:185. [PMID: 26077338 DOI: 10.1186/s12906-015-0709-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
300 Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, Kim CH, Lee HS. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis]. Korean J Hepatol. 2008;14:77-88. [PMID: 18367860 DOI: 10.3350/kjhep.2008.14.1.77] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
301 Xu Z, Zhang X, Lau J, Yu J. C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. Expert Rev Mol Med 2016;18:e16. [PMID: 27669973 DOI: 10.1017/erm.2016.16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
302 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
303 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
304 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(21): 2116-2122 [DOI: 10.11569/wcjd.v14.i21.2116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31:1927-1932. [PMID: 21546603 DOI: 10.1161/atvbaha.111.228262] [Cited by in Crossref: 99] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
306 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
307 Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17:68-80. [PMID: 26597657 DOI: 10.1111/obr.12333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
308 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
309 Xu X, Lu L, Dong Q, Li X, Zhang N, Xin Y, Xuan S. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis. 2015;14:158. [PMID: 26631018 DOI: 10.1186/s12944-015-0141-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
310 Tilg H, Moschen AR. Relevance of TNF -α gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2014;5:155-8. [DOI: 10.1586/egh.11.17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
311 Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379. [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005] [Cited by in Crossref: 288] [Cited by in F6Publishing: 280] [Article Influence: 20.6] [Reference Citation Analysis]
312 Singh MK, Jayarajan R, Varshney S, Upadrasta S, Singh A, Yadav R, Scaria V, Sengupta S, Shanmugam D, Shalimar, Sivasubbu S, Gandotra S, Sachidanandan C. Chronic systemic exposure to IL6 leads to deregulation of glycolysis and fat accumulation in the zebrafish liver. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158905. [PMID: 33582286 DOI: 10.1016/j.bbalip.2021.158905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
313 Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16:339-345. [PMID: 23493015 DOI: 10.1097/mco.0b013e3283600d46] [Cited by in Crossref: 55] [Cited by in F6Publishing: 31] [Article Influence: 6.1] [Reference Citation Analysis]
314 Cyr B, Keane RW, de Rivero Vaccari JP. ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. Int J Mol Sci 2020;21:E8580. [PMID: 33203036 DOI: 10.3390/ijms21228580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
316 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
317 Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50:1102-1111. [PMID: 19398228 DOI: 10.1016/j.jhep.2009.02.023] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 9.9] [Reference Citation Analysis]
318 Chen Y, Varghese Z, Ruan XZ. The molecular pathogenic role of inflammatory stress in dysregulation of lipid homeostasis and hepatic steatosis. Genes Dis 2014;1:106-12. [PMID: 30258859 DOI: 10.1016/j.gendis.2014.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
319 Chang CC, Wu CL, Su WW, Shih KL, Tarng DC, Chou CT, Chen TY, Kor CT, Wu HM. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Sci Rep 2015;5:10096. [PMID: 25961500 DOI: 10.1038/srep10096] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
320 Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11 Suppl 1:S209-S216. [PMID: 28017631 DOI: 10.1016/j.dsx.2016.12.033] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 10.8] [Reference Citation Analysis]
321 Wright D, Sutherland L. Antioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance. Appl Physiol Nutr Metab 2008;33:21-31. [DOI: 10.1139/h07-155] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
322 Guo L, Chen Z, Amarnath V, Yancey PG, Van Lenten BJ, Savage JR, Fazio S, Linton MF, Davies SS. Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. Antioxid Redox Signal 2015;22:1633-45. [PMID: 25751734 DOI: 10.1089/ars.2014.6078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
323 Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 2016;1:56-67. [PMID: 28404113 DOI: 10.1016/S2468-1253(16)30011-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 31] [Article Influence: 15.2] [Reference Citation Analysis]
324 Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res 2014;44:854-62. [PMID: 23834322 DOI: 10.1111/hepr.12197] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
325 Harada S, Miyagi K, Obata T, Morimoto Y, Nakamoto K, Kim KI, Kim SK, Kim SR, Tokuyama S. Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice. J Pharm Pharmacol 2017;69:698-705. [PMID: 28220495 DOI: 10.1111/jphp.12705] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
326 Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 2010;5:e13577. [PMID: 21042596 DOI: 10.1371/journal.pone.0013577] [Cited by in Crossref: 137] [Cited by in F6Publishing: 145] [Article Influence: 11.4] [Reference Citation Analysis]
327 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
328 Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(19): 3407-3417 [PMID: 28596677 DOI: 10.3748/wjg.v23.i19.3407] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
329 Okamura T, Hamaguchi M, Bamba R, Nakajima H, Yoshimura Y, Kimura T, Nishida K, Hashimoto Y, Fukuda T, Senmaru T, Fukui M. Immune modulating effects of additional supplementation of estradiol combined with testosterone in murine testosterone-deficient NAFLD model. Am J Physiol Gastrointest Liver Physiol 2020;318:G989-99. [PMID: 32363890 DOI: 10.1152/ajpgi.00310.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
330 Gudbrandsen OA, Wergedahl H, Berge RK. A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats. Nutrition. 2009;25:574-580. [PMID: 19101115 DOI: 10.1016/j.nut.2008.10.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
331 Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009;204:521-5. [DOI: 10.1016/j.atherosclerosis.2008.09.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 7.2] [Reference Citation Analysis]
332 Lim JW, Dillon J, Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World J Gastroenterol 2014; 20(26): 8325-8340 [PMID: 25024592 DOI: 10.3748/wjg.v20.i26.8325] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
333 Zhu MJ, Sun LJ, Liu YQ, Feng YL, Tong HT, Hu YH, Zhao Z. Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis. World J Gastroenterol 2008; 14(29): 4677-4683 [PMID: 18698683 DOI: 10.3748/wjg.14.4677] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
334 Kawashita E, Ishihara K, Nomoto M, Taniguchi M, Akiba S. A comparative analysis of hepatic pathological phenotypes in C57BL/6J and C57BL/6N mouse strains in non-alcoholic steatohepatitis models. Sci Rep. 2019;9:204. [PMID: 30659241 DOI: 10.1038/s41598-018-36862-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
335 Kado A, Tsutsumi T, Enooku K, Fujinaga H, Ikeuchi K, Okushin K, Moriya K, Yotsuyanagi H, Koike K. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. J Gastroenterol 2019;54:730-41. [PMID: 30830270 DOI: 10.1007/s00535-019-01565-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Reference Citation Analysis]
337 Morgantini C, Jager J, Li X, Levi L, Azzimato V, Sulen A, Barreby E, Xu C, Tencerova M, Näslund E, Kumar C, Verdeguer F, Straniero S, Hultenby K, Björkström NK, Ellis E, Rydén M, Kutter C, Hurrell T, Lauschke VM, Boucher J, Tomčala A, Krejčová G, Bajgar A, Aouadi M. Liver macrophages regulate systemic metabolism through non-inflammatory factors. Nat Metab 2019;1:445-59. [PMID: 32694874 DOI: 10.1038/s42255-019-0044-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
338 Arslan U, Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases 2020; 8(20): 4688-4699 [PMID: 33195636 DOI: 10.12998/wjcc.v8.i20.4688] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
339 Malpique R, Bassols J, López-bermejo A, Diaz M, Villarroya F, Pavia J, Congo A, de Zegher F, Ibáñez L. Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat. Int J Obes 2018;42:65-71. [DOI: 10.1038/ijo.2017.198] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
340 Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis. 2011;12:10-16. [PMID: 21091933 DOI: 10.1111/j.1751-2980.2010.00471.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
341 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
342 Canup BS, Song H, Le Ngo V, Meng X, Denning TL, Garg P, Laroui H. CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice. Dig Liver Dis 2017;49:188-96. [PMID: 27939923 DOI: 10.1016/j.dld.2016.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
343 Page S, Birerdinc A, Estep M, Stepanova M, Afendy A, Petricoin E, Younossi Z, Chandhoke V, Baranova A. Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example. PLoS One 2013;8:e56009. [PMID: 23405244 DOI: 10.1371/journal.pone.0056009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
344 Bieghs V, Rensen PC, Hofker MH, Shiri-sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 2012;220:287-93. [DOI: 10.1016/j.atherosclerosis.2011.08.041] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
345 Lee SA, Lee SY, Choi YM, Kim H, Kim BJ. Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region. World J Gastroenterol 2018; 24(10): 1084-1092 [PMID: 29563753 DOI: 10.3748/wjg.v24.i10.1084] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
346 Abu-Serie MM, El-Gamal BA, El-Kersh MA, El-Saadani MA. Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis. Lipids Health Dis 2015;14:128. [PMID: 26463841 DOI: 10.1186/s12944-015-0124-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
347 Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS One 2012;7:e34218. [PMID: 22514624 DOI: 10.1371/journal.pone.0034218] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
348 Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Review of Gastroenterology & Hepatology 2015;9:1055-67. [DOI: 10.1586/17474124.2015.1056156] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
349 Otterdal K, Haukeland JW, Yndestad A, Dahl TB, Holm S, Segers FM, Gladhaug IP, Konopski Z, Damås JK, Halvorsen B, Aukrust P. Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. Clin Transl Gastroenterol 2015;6:e95. [PMID: 26133108 DOI: 10.1038/ctg.2015.23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
350 Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, Wang H, Zhao G, Liang W, Koike Y, Lu H, Koike T, Hayek T, Pennathur S, Xi C, Wen B, Sun D, Garcia-Barrio MT, Aviram M, Gottlieb E, Mor I, Liu W, Zhang J, Chen YE. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med 2020;12:eaaz2841. [PMID: 33268508 DOI: 10.1126/scitranslmed.aaz2841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
351 Xiong L, Ren F, Lv J, Zhang H, Guo H. Lactoferrin attenuates high-fat diet-induced hepatic steatosis and lipid metabolic dysfunctions by suppressing hepatic lipogenesis and down-regulating inflammation in C57BL/6J mice. Food Funct 2018;9:4328-39. [DOI: 10.1039/c8fo00317c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
352 Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med. 2009;47:1055-1062. [PMID: 19634983 DOI: 10.1515/cclm.2009.244] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
353 Kovalic AJ, Cholankeril G, Satapathy SK. Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Transl Gastroenterol Hepatol. 2019;4:65. [PMID: 31620647 DOI: 10.21037/tgh.2019.08.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
354 Zhao Y, Zhao G, Chen Z, She Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension 2020;75:275-84. [DOI: 10.1161/hypertensionaha.119.13419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 10.5] [Reference Citation Analysis]
355 Gentile CL, Frye MA, Pagliassotti MJ. Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 2011;37:8-16. [PMID: 21328622 DOI: 10.1002/biof.135] [Cited by in Crossref: 97] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
356 Mallick P, Shah P, Gandhi A, Ghose R. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life Sci 2015;139:132-8. [PMID: 26334566 DOI: 10.1016/j.lfs.2015.08.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
357 Baranova A, Randhawa M, Jarrar M, Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics 2014;7:195-205. [DOI: 10.1586/14737159.7.2.195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
358 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014. 00177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]